Merck & Co., Inc. (MRK)

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.

Where These 4 Sector ETFs Stand Heading Into Year-End

As 2026 winds down, the article analyzes four key sector ETFs heading into 2027. Technology stocks have pulled back 14% from October highs after AI companies missed earnings, but the sector remains reasonably valued. Financial stocks are mixed, with insurance outperforming while banks struggle amid tepid loan demand. Energy stocks surged 40% YTD on oil prices but face headwinds as crude may have peaked around $90/barrel. Healthcare stocks are up 21% but appear slightly overvalued at current levels.

Merck Says EMA’s CHMP Recommends Approval Of Welireg Plus Lenvatinib For Advanced Clear Cell Renal Cell Carcinoma After PD-1/PD-L1 Inhibitor; EC Decision Expected Within Two Months

Merck Says FDA Set March 22, 2027 PDUFA Date For Enflonsia Second-Season sBLA

Merck Says EMA’s CHMP Recommends Approval Of Expanded Enflonsia Indication To Prevent RSV In At-Risk Children Up To 24 Months Through Second RSV Season; EC Decision Expected Within Two Months